Pulmonx Corporation is a commercial-stage medical technology company. The Company is focused on providing planning tools and treatments for obstructive lung disease. Its solutions include Zephyr Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform. The Company's solutions offer minimally invasive treatment option for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.
Company profile
Website
CEO
Jared B. Bauer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
FRESH MEDICAL LABORATORIES, INC.
SEC CIK
Corporate docs
IRS number
201922768
Latest filings (excl ownership)
8-K
Other Events
1 Sep 23
NT 10-Q
Notice of late quarterly filing
15 Aug 23
10-Q
2023 Q1
Quarterly report
22 May 23
NT 10-Q
Notice of late quarterly filing
12 May 23
10-K
2022 FY
Annual report
17 Apr 23
NT 10-K
Notice of late annual filing
30 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
28 Jun 22
10-Q
2022 Q1
Quarterly report
23 May 22
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 842.13 k | 842.13 k | 842.13 k | 842.13 k | 842.13 k | 842.13 k |
Cash burn (monthly) | (no burn) | 34.17 k | 189.55 k | 211.20 k | 121.25 k | 151.86 k |
Cash used (since last report) | n/a | 408.50 k | 2.27 mm | 2.52 mm | 1.45 mm | 1.82 mm |
Cash remaining | n/a | 433.63 k | -1.42 mm | -1.68 mm | -607.43 k | -973.44 k |
Runway (months of cash) | n/a | 12.7 | -7.5 | -8.0 | -5.0 | -6.4 |